Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Access and SpePharm announce licensing of MuGard for Europe
SpePharm will market MuGard in Europe for the treatment of oral mucositis

Dallas, Texas, USA / Amsterdam, The Netherlands, August 27, 2007. Access Pharmaceuticals, Inc. (OTC BB: ACCP) and SpePharm Holding, B.V. today announced the signing of a definitive licensing agreement under which SpePharm will market Access's product MuGard(tm) in Europe.

MuGard(tm) is Access' proprietary product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. MuGard has received marketing allowance in the United States from the Food and Drug Administration under a 510(k) procedure.

SpePharm will be responsible for marketing MuGard throughout the European Union plus Switzerland, Norway and Iceland, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory.

'We are very excited about the opportunity to commercialize MuGard in Europe,' said Jean-François Labbé, CEO of SpePharm. 'We believe MuGard has the potential to address an area of significant unmet medical need in supportive care of cancer patients. Moreover, MuGard is an excellent complement to our existing product, Loramyc, and strengthens our strategic focus in this important therapeutic area. We anticipate launching MuGard during 2008 and expect to have a dedicated sales force of 50-60 representatives across Europe promoting both MuGard and Loramyc.'

'SpePharm is an ideal partner for us in Europe,' added Stephen R. Seiler, President and CEO of Access. 'We are excited about the focus SpePharm will bring to MuGard and the tremendous fit with Loramyc. Jean-François and his team bring a wealth of experience and professionalism which we believe will benefit the development and marketing of MuGard.'

In connection with the exclusive Licensing Agreement, SpePharm will pay Access an upfront fee and substantial royalties on net sales.

About MuGard(tm):

MuGard is a ready-to-use mucoadhesive oral wound rinse. The mucoadhesive formulation forms a protective coating over the oral mucosa when washed around the mouth. In a retrospective comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group.

Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.

About SpePharm Holding, BV:

SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam, and an operational base in Paris, France. SpePharm is an emerging pan-European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines essentially for the hospital and specialty markets. Particularly areas of therapeutic interest are in oncology, haematology, critical & supportive care and endocrinology. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe.

SpePharm was founded in September 2006 by Jean-François Labbé together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-François Labbé is a former senior executive at Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management. SpePharm, through its founding management team, has a proven track record of successful development, registration, and/

Publisher Contact Information:

SpePharm Holding, B.V.
+33 (0) 1 56 60 52 46

Company profile of SpePharm Holding, B.V.
Past press releases of SpePharm Holding, B.V..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.